CBAY enters Uptrend as Momentum indicator ascends above 0 levelThis indicator may be signaling that CBAY's price has momentum to move higher, since its current price exceeds the price logged 14 days ago. Traders may consider buying the stock or exploring call options. I backtested 91 similar cases where CBAY's Momentum Indicator exceeded 0, and 78 of them led to a successful outcome. Odds of Success: 86%.
Biotechnology
Biotech Looking a Little Sick: LABDAnother descending triangle has appeared in LABD. My numerous other finds have yielded decent results but we have yet to see a turn in the market indicating a new direction. The play itself might be worth a couple of percent gain but please trade safely. The downturn near the end of Friday's session is forecasting a likely poor Monday opening in addition to the negative news that continues to come out of the ECB and New York.
ACAD MA MACD Histogram just turned positiveA buy signal is generated. This is a Bullish indicator signaling ACAD's price could rise from here. Traders may explore going long the stock or buying call options. I identified 45 similar cases where ACAD's MACD histogram became positive, and 38 of them led to successful outcomes. Odds of Success: 84%.
ALNY price moved above its 50-day MA on June 17, 2020This price move could indicate a change in the trend, and may be a buy signal for investors.I found 43 similar cases, and 43 were successful. Based on this data, the odds of success are 90%.
ALNY price moved above its 50-day MA on June 17, 2020A buy signal is generated. This price move could indicate a change in the trend and may be a buy signal for investors. I found 43 similar cases, and 43 were successful. Based on this data, the odds of success are 90%.
Novavax, Inc. (NVAX) long.All description on the chart.
Please, don't forget to like and follow.
Thank you.
Merck has upside to $82Analyst forecasts for Merck earnings came down sharply early this year, but lately they've stabilized and even ticked upward a little. Merck is still priced for an optimistic market, with forward P/E around 15 and PEG around 2-3. This is reasonable for a large cap company with 3% dividend and a great reputation, but it's not bargain pricing, exactly. A second round of lockdowns or a second wave of Covid-19 could hurt the stock again.
But as long there's no major deterioration of the macroeconomic outlook, the fair value range for Merck is about $75-82 per share. Analysts have been slow to make any forecasts for 2022 due to macroeconomic uncertainty, but I predict that the top end of the fair value range will shift upward to $87 per share once the 2022 forecasts finally come in.
Merck is oversold today on the hourly RSI and curling upward. MACD is below the signal line, but also curling upward. A few minutes ago Merck announced an FDA approval to expand the label for GARDASIL, its HPV drug. I suspect this may function as a catalyst to send Merck back upward toward $82 per share. I bought some shares after-hours, and if I can get in cheap enough, I will consider some call options tomorrow with maybe a one-month expiration.
NOVNNOVN sitting right below 50 ema and above POC 100 ema around .64 & VPVR is non existant above .77c
Sage Therapeutics (SAGE) long.All description on the chart.
Please, don't forget to like and follow.
Thank you.
CVM About to Start New RallyWeekly Chart :
AMEX:CVM Finished the Major Down Trend on April 2019, and from then is in a solid Secondary Up Trend.
Note 13.50 Historical level, which serve us as a good support to form a trade.
Daily Chart :
Minor Down Trend about to end (Yellow):
Line Chart :
The Trade Plan :
Wait for a Clear Bullish Minor sign -
1. Strong buying Candle on 13.50 Level .
2. Retest of the Orange Trendline and closing above the Yellow Trendline.
Only for investors : Biotech For those looking to diversify their portfolio or a long-term investment. Here I bring you an option in the biotech sector: Bluebird Bio INC, the leader in targeted cell therapy.
This stock is in an important support area. It is a zone where buyers will seek to accumulate to buy cheap. the risk in this operation is low compared to the profit potential
GOSS long poition
GOSS Company Gossamer Bio, Inc., USA, Industry Biotechnology
Market Cap 953.81M
EPS next 5Y 31.90%
AnaptysBio #ANAB can shoot long position target 30$
AnaptysBio #ANAB can shoot long position target 30$
EPS Q/Q 63.00%
COMPUGEN $CGEN "BREAKINGOUT"It is breaking the buy point out today. The volume is about to exceed the average. watch for channel resistances.
12 months Consensus Price Target: $18.57
if you find my charts useful, please leave me "like" or "comment".
Please don't trade according to the ideas, rely on your own knowledge.
Thx
Big Biotechs Ascending TriangleIBB is forming an ascending triangle, which is a continuation pattern after the breakout.
Important to note the 20sma, which has been very supportive in the trend. The is also some support we can see many candlesticks with bottom wicks, meaning the shorts were met with buyers very quickly.
ONTX - Could Breakout, How Far?All,
ONTX is overdue for a takeoff. Today it is at +30% premarket, but this is why you do TA and watch Volume at open. It will gap above both blue lines for support and .44/.45 are aboth huge support lines. My theory is simple it may sell off around .53. However, I would hold and wait for the rally at .39 or .44 to push back up to .70-.75. The question there becomes will it break or fail that area on second re test?
ALSO FIRST THING IS FIRST WATCH THE MARKET BEFORE YOU BUY ANY STOCK. S&P / NASDAQ AND WATCH VOLUME ON INVERSE S&P ETFS.
AGEN - See Past Post - This ride isn't overAll,
See my previous post on my baby aka favorite stock. My entry was $2.28 on this. There pipeline was epic, FDA approvals and no price movement. Now it just hit every scanner and radar out there. I would not buy in now of course, but over time it will come back and retest the last high it left from. It may happen quickly but I would put my alert around 50% of the big bar. I will update later on re buy ins for this stock.
$ADAP can rise in the next daysContextual immersion trading strategy idea.
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States.
Friday morning the company presented positive data on its experimental cell therapy, which is designed to treat a range of cancers. It causes a rise in the share price. I see some preconditions the share price will continue growing.
The demand for shares of the company still looks higher than the supply.
These and other conditions can cause a rise in the share price in the next days.
So I opened a long position from $11,85;
stop-loss — $11,18.
Information about take-profits will be later.
Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision.
Always do your own analysis before making deals. When you use any materials, do not rely on blind trust.
You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy.
If you like my content, you can subscribe to the news and receive my fresh ideas.
Thanks for being with me!
GNBT: This looks promising to me. I like the major increase in volume. and the EWT look to this. Up about 8% today so far tody. Is a Biotech so is SPECULATIVE so be careful with size of position.. If count is correct there is a possibility of major gains. Bullish candle on the daily chart so far. Could use a close below today's close as a stop. Process your way.
From Zacks: Generex Biotechnology Corporation provides research, development, and commercialization of drug delivery systems and technologies. The company's products include Generex Oral-lyn, Glucose RapidSpray, BaBOOM Energy Spray and Crave-NX. It markets its products primarily in Ecuador, Canada, and the United States. Generex Biotechnology Corporation is based in Toronto, Canada.
$CERC can rise in the next daysContextual immersion trading strategy idea.
Cerecor Inc., a pharmaceutical company, focuses on pediatric health care.
The company announced it has received clearance from the U.S. Food and Drug Administration (FDA) to proceed with a proof-of-concept clinical trial of its anti-LIGHT monoclonal antibody CERC-002 in patients with COVID-19 cytokine storm induced Acute Respiratory Distress Syndrome (ARDS).
The demand for shares of the company looks higher than the supply.
These and other conditions can cause a rise in the share price in the next days.
So I opened a long position from $2,97;
stop-loss — $2,76.
Information about take-profits will be later.
Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision.
Always do your own analysis before making deals. When you use any materials, do not rely on blind trust.
You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy.
If you like my content, you can subscribe to the news and receive my fresh ideas.
Thanks for being with me!
MNLO - FDA Approval - Trend Is Your FriendAll,
I think this is a buy and hold over weekend scenario. FDA approval is no joke (well at least in trading ;) lol). I think this is a gap up Monday and overall could double actually based on chart positioning.
TA Wise: we are forming an ascending triangle and topping out. However this is a bullish pattern. Very clear on 4H vs 15M we have yet to break full candle above just fake out candles.
RXMD - Roll the Dice on the OTC?First off, THIS IS A RISKY BET. I got in at .082 yes... less than a dime. There was news they are doing antibody COVID testing. This got 40M volume x8 its relative volume. Like I said extremely risky. Watch it today and see what happens. Personally I just bought 3000 shares because I don't care if I lose $250 just to see.
finance.yahoo.com
